A recent study demonstrated that targeting CXCR4 could enhance the efficacy of PD-1 immunotherapy by modulating the tumor microenvironment, primarily through the reduction of myeloid-derived suppressor cells. The gene discussed is CXCR4; the disease is neoplasm.